Second-generation long-acting injections anti-psychotics improve executive functions in patients with schizophrenia: a 12-month real-world study

References

• Andreasen NC, Carpenter WT, Kane JM, Lasser RA, Marder SR, Weinberger DR. 2005. Remission in schizophrenia: proposed criteria and rationale for consensus. Am J Psychiaty. 162(3):441–449.
   PubMed Web of Science ®Google Scholar
• Bervoets C, Morrens M, Vansteelandt K, Kok F, de Patoul A, Halkin V, Pitsi D, Constant E, Peuskens J, Sabbe B. 2012. Effect of aripiprazole on verbal memory and fluency in schizophrenic patients. CNS Drugs. 26(11):975–982.
   PubMed Web of Science ®Google Scholar
• Berzon RA, Donnelly MA, Simpson RL, Simeon GP, Tilson HH. 1995. Quality of life bibliography and indexes: 1994 update. Qual Life Res. 4(6):547–569.
   PubMed Web of Science ®Google Scholar
• Brissos S, Veguilla MR, Taylor D, Balanzá-Martinez V. 2014. The role of long-acting injectable antipsychotics in schizophrenia: a critical appraisal. Therap Adv Psychopharmacol. 4(5):198–219.
   PubMedGoogle Scholar
• Brugnoli R, Rapinesi C, Kotzalidis GD, Marcellusi A, Mennini FS, De Filippis S, Carrus D, Ballerini A, Francomano A, Ducci G, et al. 2016. Model of Management (Mo.Ma) for the patient with schizophrenia: crisis control, maintenance, relapse prevention, and recovery with long-acting injectable antipsychotics (LAIs). Riv Psichiatr. 51(2):47–59.
   PubMed Web of Science ®Google Scholar
• Correll CU, Citrome L, Haddad PM, Lauriello J, Olfson M, Calloway SM, Kane JM. 2016. The use of long-acting injectable antipsychotics in schizophrenia. J Clin Psychiatry. 77(Suppl 3):1–24.
   PubMed Web of Science ®Google Scholar
• Cuomo I, Kotzalidis GD, de Persis S, Piacentino D, Perrini F, Amici E, De Filippis S. 2018. Head-to-head comparison of 1-year aripiprazole long-acting injectable (LAI) versus paliperidone LAI in comorbid psychosis and substance use disorder: impact on clinical status, substance craving, and quality of life. Neuropsychiatr Dis Treat. 14:1645–1656.
   PubMed Web of Science ®Google Scholar
• Emsley R, Kilian S. 2018. Efficacy and safety profile of paliperidone palmitate injections in the management of patients with schizophrenia: an evidence-based review. Neuropsychiatr Dis Treat . 14:205–223.
   PubMed Web of Science ®Google Scholar
• Emsley R, Kilian S, Phahladira L. 2016. How long should antipsychotic treatment be continued after a single episode of schizophrenia?. Curr Opin Psychiatry. 29(3):224–229.
   PubMed Web of Science ®Google Scholar
• Fagiolini A, Rocca P, De Giorgi S, Spina E, Amodeo G, Amore M. 2017. Clinical trial methodology to assess the efficacy/effectiveness of long-acting antipsychotics: randomized controlled trials vs naturalistic studies. Psychiatry Res. 247:257–264.
   PubMed Web of Science ®Google Scholar
• Fleischhacker WW, Gopal S, Lane R, Gassmann-Mayer C, Lim P, Hough D, Remmerie B, Eerdekens M. 2012. A randomized trial of paliperidone palmitate and risperidone long-acting injectable in schizophrenia. Int J Neuropsychopharmacol. 15(1):107–118.
   PubMed Web of Science ®Google Scholar
• Golden C. 1978. Stroop color and word test: a manual for clinical and experimental uses. Chiacago, IL: Skoelting.
   Google Scholar
• Harvey PD, Keefe RSE. 2001. Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment. Am J Psychiatry. 158(2):176–184.
   PubMed Web of Science ®Google Scholar
• Hori H, Katsuki A, Atake K, Yoshimura R. 2018. Effects of continuing oral risperidone vs. switching from risperidone to risperidone long-acting injection on cognitive function in stable schizophrenia patients: a pilot study. Front Psychiatry. 9:74.
   PubMed Web of Science ®Google Scholar
• Hori H, Yoshimura R, Katsuki A, Atake K, Igata R, Konishi Y, Beppu H, Tominaga H. 2017. Blood biomarkers predict the cognitive effects of aripiprazole in patients with acute schizophrenia. IJMS. 18(3):568.
   Google Scholar
• Hori H, Yoshimura R, Katsuki A, Hayashi K, Ikenouchi-Sugita A, Umene-Nakano W, Nakamura J. 2012. The cognitive profile of aripiprazole differs from that of other atypical antipsychotics in schizophrenia patients. Journal of Psychiatric Research. 46(6):757–761.
   PubMed Web of Science ®Google Scholar
• Jann MW, Penzak SR. 2018. Long-acting injectable second-generation antipsychotics: an update and comparison between agents. CNS Drugs. 32(3):241–257.
   PubMed Web of Science ®Google Scholar
• Kahn RS, Sommer IE, Murray RM, Meyer-Lindenberg A, Weinberger DR, Cannon TD, O'Donovan M, Correll CU, Kane JM, van Os J. 2015. Schizophrenia. Nat Rev Dis Primers. 1(1):15067.
   PubMed Web of Science ®Google Scholar
• Kane JM, Zhao C, Johnson BR, Baker RA, Eramo A, McQuade RD, Duca AR, Sanchez R, Peters-Strickland T. 2015. Hospitalization rates in patients switched from oral anti-psychotics to aripiprazole once-monthly: final efficacy analysis. J Med Econ. 18(2):145–154.
   PubMed Web of Science ®Google Scholar
• Kay SR, Fiszbein A, Opler LA. 1987. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophrenia Bull. 13(2):261–276.
   PubMed Web of Science ®Google Scholar
• Kim E, Correll CU, Mao L, Starr HL, Alphs L. 2016. Once-monthly paliperidone palmitate compared with conventional and atypical daily oral antipsychotic treatment in patients with schizophrenia. CNS Spectr. 21(6):466–477.
   PubMed Web of Science ®Google Scholar
• Kim S-W, Chung Y-C, Lee Y-H, Lee J-H, Kim S-Y, Bae K-Y, Kim J-M, Shin I-S, Yoon J-S. 2012. Paliperidone ER versus risperidone for neurocognitive function in patients with schizophrenia. Int Clin Psychopharmacol. 27(5):267–274.
   PubMed Web of Science ®Google Scholar
• Kishimoto T, Robenzadeh A, Leucht C, Leucht S, Watanabe K, Mimura M, Borenstein M, Kane JM, Correll CU. 2014. Long-acting injectable vs oral antipsychotics for relapse prevention in schizophrenia: a meta-analysis of randomized trials. Schizophrenia Bull. 40(1):192–213.
   PubMed Web of Science ®Google Scholar
• Koshikawa Y, Takekita Y, Kato M, Sakai S, Onohara A, Sunada N, Nishida K, Yoshimura M, Fabbri C, Serretti A. 2016. The comparative effects of risperidone long-acting injection and paliperidone palmitate on social functioning in schizophrenia: a 6-month, open-label, randomized controlled pilot trial. Neuropsychobiology. 73(1):35–42.
   PubMed Web of Science ®Google Scholar
• Morosini PL, Magliano L, Brambilla L, Ugolini S, Pioli R. 2000. Development, reliability and acceptability of a new version of the DSM-IV Social and Occupational Functioning Assessment Scale (SOFAS) to assess routine social functioning. Acta Psychiatr Scand. 101(4):323–329.
   PubMed Web of Science ®Google Scholar
• Naber D, Hansen K, Forray C, Baker RA, Sapin C, Beillat M, Peters-Strickland T, Nylander A-G, Hertel P, Andersen HS. 2015. Qualify: a randomized head-to-head study of aripiprazole once-monthly and paliperidone palmitate in the treatment of schizophrenia. Schizophrenia Res. 168(1-2):498–504.
   PubMed Web of Science ®Google Scholar
• Olivares JM, Rodriguez-Morales A, Diels J, Povey M, Jacobs A, Zhao Z, Lam A, e-STAR Spanish Study Group. 2009. Long-term outcomes in patients with schizophrenia treated with risperidone long-acting injection or oral antipsychotics in Spain: results from the electronic Schizophrenia Treatment Adherence Registry (e-STAR). Eur Psychiatry. 24(5):287–296.
   PubMed Web of Science ®Google Scholar
• Ostuzzi G, Bighelli I, So R, Furukawa TA, Barbui C. 2017. Does formulation matter? A systematic review and meta-analysis of oral versus long-acting antipsychotic studies. Schizophrenia Res. 183:10–21.
   PubMed Web of Science ®Google Scholar
• Owen MJ, Sawa A, Mortensen PB. 2016. Schizophrenia. Lancet. 388(10039):86–97.
   PubMed Web of Science ®Google Scholar
• Pae C-U, Wang S-M, Han C, Bahk W-M, Lee S-J, Patkar AA, Masand PS, Serretti A, Emsley R. 2017. Comparison between long-acting injectable aripiprazole versus paliperidone palmitate in the treatment of schizophrenia. Int Clin Psychopharmacol. 32(5):235–248.
   PubMed Web of Science ®Google Scholar
• Rey A. 1941. L’examen psychologique dans les cas d’encéphalopathie traumatique. Archives de Psychologie. 28:215–285.
   Google Scholar
• Robinson D, Woerner MG, Alvir JMJ, Bilder R, Goldman R, Geisler S, Koreen A, Sheitman B, Chakos M, Mayerhoff D. 1999. Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch Gen Psychiatry. 56(3):241–247.
   PubMed Web of Science ®Google Scholar
• Rocca P, Montemagni C, Frieri T. 2016. Second-generation long-acting injectable antipsychotics in schizophrenia: patient functioning and quality of life. Neuropsychiatr Dis Treat. 12:917–929.
   PubMed Web of Science ®Google Scholar
• Schreiner A, Aadamsoo K, Altamura AC, Franco M, Gorwood P, Neznanov NG, Schronen J, Ucok A, Zink M, Janik A. 2015. Paliperidone palmitate versus oral antipsychotics in recently diagnosed schizophrenia. Schizophrenia Res. 169(1-3):393–399.
   PubMed Web of Science ®Google Scholar
• Schreiner A, Bergmans P, Cherubin P, Hargarter L. 2017. The effect of long-acting paliperidone palmitate once-monthly on negative and depressive symptoms in patients with schizophrenia switched from previous unsuccessful treatment with oral aripiprazole. Therap Adv Psychopharmacol. 7(2):59–65.
   PubMed Web of Science ®Google Scholar
• Suzuki H, Hibino H, Inoue Y, Matsumoto H, Mikami K. 2017. The effect of switching from oral low-dose aripiprazole to aripiprazole once-monthly 300 mg on the quality of life in three patients with schizophrenia. SAGE Open Med Case Rep. 5:2050313X1771059.
   Web of Science ®Google Scholar
• Suzuki H, Hibino H, Inoue Y, Takaya A. 2016. Comparison of treatment retention between risperidone long-acting injection and first-generation long-acting injections in patients with schizophrenia for 5 years. J Clin Psychopharmacol. 36(4):405–406.
   PubMed Web of Science ®Google Scholar
• Takekita Y, Koshikawa Y, Fabbri C, Sakai S, Sunada N, Onohara A, Nishida K, Yoshimura M, Kato M, Serretti A. 2016. Cognitive function and risperidone long-acting injection vs. paliperidone palmitate in schizophrenia: a 6-month, open-label, randomized, pilot trial. BMC Psychiatry. 16(1):172.
   PubMedGoogle Scholar
• Waddell L, Taylor M. 2009. Attitudes of patients and mental health staff to antipsychotic long-acting injections: systematic review. Br J Psychiatry. 52(S52):S43–S50.
   Google Scholar
• World Medical Association. 2013. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 310(20):2191.
   PubMed Web of Science ®Google Scholar